Myriad Genetics (MYGN) Investor Day 2024 summary

Strategic direction and growth outlook

• Targeting sustained 12%+ annual revenue growth, driven by hereditary cancer, women's health, and pharmacogenomics, with multiple levers for expansion including new product launches and market share gains in underpenetrated segments.

• Investments in operational excellence, digital infrastructure, EMR integration, and AI-driven workflows have improved productivity, customer experience, and enabled a scalable model, supporting industry-leading gross margins of 70%+.

• Portfolio expansion includes new offerings in oncology (Precise Tumor, MRD), women's health (FirstGene, expanded Foresight), and earlier gestational testing, with a focus on clinical utility, guideline expansion, and payer coverage.

• Ongoing innovation in AI, automation, and next-generation sequencing is enhancing product differentiation, reducing costs, and accelerating turnaround times, supported by Labs of the Future and automation initiatives.

• Strategic management of supply chain and disciplined OpEx growth (6%-7%) are expected to support profitability and reinvestment in R&D and technology.

Financial guidance and performance

• Achieved 13% annual revenue growth through Q2 2024, with double-digit growth across core product lines: GeneSight (16%), hereditary cancer (15%), Prolaris (10%), and prenatal (37%).

• Reaffirmed 2024 revenue guidance of $835M–$845M (11%-12% YoY growth), with Q3 revenue expected at $210M–$212M despite seasonal softness.

• Long-term targets include maintaining or growing gross margins (70%+), double-digit adjusted EBITDA margins by 2026, and continued investment in high-impact areas.

• Path to $1B+ revenue in 2026, driven by mid-teens growth in women's health and low double-digit growth in hereditary cancer.

• Operational leverage and disciplined expense management expected to support margin expansion and free cash flow growth.

Product and market development

• Hereditary cancer remains a cornerstone, with MyRisk and RiskScore driving growth through expanded use cases, guideline changes, and increased adoption in both affected and unaffected populations.

• Women's health is a major growth engine, with expanded carrier screening, earlier prenatal testing (Prequel at 8 weeks), and the launch of FirstGene addressing unmet needs and improving margins.

• GeneSight pharmacogenomics business is profitable and growing, with increased adoption among prescribers and ongoing expansion into new indications and coverage wins.

• Oncology pipeline includes expansion of MyChoice into new indications, launch of Precise Tumor and MRD, and strategic partnerships with leading cancer centers, with a 2026 commercial launch target for breast cancer.

• Evidence generation and collaborative research are central, with over 40 active studies and a large de-identified patient registry supporting clinical utility and payer engagement.